Procter & Gamble
Executive Summary
Will begin construction of a $ 280 mil. worldwide health care R&D headquarters in 1992. Located on 253 acres in suburban Cincinnati, the facility is expected to open in 1995 and to employ about 1,000. P&G says its Norwich Eaton Pharmaceuticals unit will remain based in Norwich, N.Y.; however, the upstream prescription drug research and regulatory/medical affairs organizations now located in Norwich will move to the new center. Rich-Vicks facility in Shelton, Connecticut will close by late 1992. . . .
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth